Emergent BioSolutions: Statement from the Emergent BioSolutions Board of Directors

Gaithersburg, Md.- We mourn the loss of our Founder and former CEO and Executive Chairman, Fuad El-Hibri, who passed away peacefully at his home early Saturday surrounded by his family and loved ones. Our thoughts are with his wife, Nancy, his children and grandchildren, and his friends.

Fuad founded Emergent (then BioPort) in 1998 with a single product, BioThrax® (Anthrax Vaccine Adsorbed), and took the company public in 2006. After serving as CEO for nearly 14 years until March 2012, and Chairman executive for 10 years until his retirement in March 2022, Fuad was instrumental in growing the company’s portfolio to its current line of marketed and procured products for a variety of public health threats, including including medical countermeasures against anthrax, smallpox, botulism and chemical warfare agents, as well as overseeing the company’s role in addressing the opioid crisis.

Under Fuad’s leadership, Emergent has delivered over 120 million equivalent doses of COVID-19 vaccine and established a trusted partnership with the U.S. government, including providing anthrax and smallpox vaccines for the army and stocks for US biodefense. Additionally, its focus on quality manufacturing of complex biologics has resulted in a full range of CDMO development, drug substance and drug product manufacturing and packaging services.

Fuad’s passion for Emergent’s mission – to protect and enhance lives – is the foundation of the company’s success. His dedication to public health and preparedness inspires us to continue building a healthier and safer world. We remain forever grateful for Fuad’s entrepreneurial spirit, bold vision and generous heart.

In lieu of flowers, his family asks that you consider contributing to the El-Hibri Foundation at: 1420 16th Street NW, Washington, DC 20036 or making a online donation.


Emergent BioSolutions Inc. published this content on April 25, 2022 and is solely responsible for the information contained therein. Distributed by Audienceunedited and unmodified, on Apr 25, 2022 11:48:11 AM UTC.